Liothyronine sodium - Treatment resistant depression
You are here : Home > Formulary Search > Liothyronine sodium - Treatment resistant depression
Status 1
- Capsules
- Tablets
Initiation by consultant psychiatrists / specialist mental health team only
Status 2
- Oral solution
The oral solution has not been reviewed for addition to the formulary. Please contact your Pharmacy Team for advice.
This formulation has not yet been assessed for formulary status and is not currently on the APC work-plan.
It has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing, it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.
Documentation
PAD Profile
Other Indications
Below are listed other indications that Liothyronine sodium is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Treatment resistant depression.
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed that the decision made by APC in March 2016 still stands and a RED traffic light status for Liothyronine (T3) as an option for treatment resistant depression in a niche group of adults whose depression has failed to respond to several antidepressants and is intolerant to lithium augmentation.
Where liothyronine is prescribed for the treatment of depression only, this should be under the care of an NHS consultant psychiatrist.
The most cost-effective formulation should be prescribed at initiation.